Tumor cells
Tumor cells are the malignant cellular component of a cancerous tumor.
Tumor cells are the malignant cellular component of a cancerous tumor. They arise from genetic and epigenetic alterations that disrupt normal control of proliferation, survival, differentiation, and interaction with the surrounding tumor microenvironment. As a result, tumor cells can acquire properties such as unchecked growth, resistance to apoptosis, immune evasion, invasive behavior, and drug resistance. Their biology is strongly shaped by signals from the tumor microenvironment, including cytokines, metabolic stress, and interactions with stromal cells, immune cells, and extracellular matrix.
In biomedical research, tumor cells are a central therapeutic target for chemotherapy, photochemotherapy, photothermal therapy, immunotherapy, and nanomedicine-based drug delivery. Many recent studies have focused on selectively directing agents to tumor cells, reversing chemoresistance, or inducing immunogenic cell death and cytotoxicity. In these contexts, pathways involving transforming growth factor, reactive oxygen species, glutathione metabolism, and immune checkpoints can influence how tumor cells respond to treatment and how effectively the tumor can be controlled.
Rebuilt from PubMed 18 Sept 2026 · no new papers today
Where the papers sit
25 papers study tumor cells directly. The themes below are drawn from those 25.
-
Ferroptosis and Immunogenic Cell Death : Nanotherapies increasingly combine reactive oxygen species, ferroptosis, apoptosis and immunogenic cell death with checkpoint blockade or in situ vaccination. PD-L1 targeting, cancer-associated fibroblast reprogramming and free-radical delivery aim to overcome immune resistance in melanoma, hepatocellular carcinoma and other solid tumors. 9 papers · 36%
-
Cancer Immunotherapy and Immune Modulation : Immune engineering is moving toward broader, more programmable responses through CAR-T and natural killer cell modification, tumor-immune profiling and ecosystem targeting. Microbiota metabolites, exercise, tumor-specific antibodies and nanozyme therapy recur as response modulators. 8 papers · 32%
-
Mechanisms of Cancer Chemoresistance : Chemoresistance is treated as a tumor–stroma problem involving cancer-associated fibroblasts, mitophagy and pyrimidine metabolism. Dual-targeted combination delivery, siRNA, photothermal therapy and temozolomide aim to reverse resistance across colorectal, pancreatic and breast cancers. 6 papers · 24%
-
Targeted Protein Degradation Platforms : Magnetic extracellular vesicles and platelet-based lysosome-targeting systems are being developed to deliver degraders selectively. CD274 and lysosomal sorting recur as targets, with in vitro and in vivo validation advancing programmable protein removal. 2 papers · 8%
Recent Findings on tumor cells
Cancer Therapeutic Strategies: Iron-deprivation liposomes, biomimetic nanoparticles, extracellular vesicles, nanogels, and bacteria-activated nanozymes improve delivery to tumor cells 42711711Sep42486784Jul42474418Jul42229647Jun42053349Apr42170851May. These platforms combine chemotherapy with ferroptosis, apoptosis, photothermal therapy, sonodynamic therapy, chemodynamic therapy, or cuproptosis 42711711Sep42402299Jul42315000Jun42295973Jun42474418Jul. Several strategies reverse resistance by silencing MGMT, remodeling M2-like tumor-associated macrophages, blocking CAF-driven pyrimidine metabolism, or reducing oxidative-stress defenses 42315000Jun42486784Jul42202065May42170851May41936879Apr. Immune-directed approaches enhance treatment through immunogenic cell death, dendritic cell maturation, CD8-positive T-cell infiltration, engineered CAR-T cells, TIGIT-edited NK cells, and ACE-iMac macrophages 42486097Jul42619089Aug41916312Mar41982126Apr41968179Apr. UBC9 and PI3K co-expression marks poor prognosis and chemoresistance in colorectal cancer, whereas exercise scheduling produces a different result: higher frequency reduced tumor suppression when total exercise volume remained fixed 42522541Jul42049052Apr.
Written from 25 PubMed abstracts, each one cited by PMID above. Published: 2026-08-19. Last written: 2026-09-11 by GPT. Drafted by language models from published abstracts; not medical advice.